



506.44792X00

JC10 Rec'd PCTO 23 JUN 2005

#3  
PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. SAKI, et al.  
Serial No.: 10/525,326  
Filed: FEBRUARY 22, 2005  
Title: AGENT FOR PREVENTION AND/OR TREATMENT OF  
ASTHMA  
Group AU: Unassigned  
Examiner: Unassigned  
Confirm. No.: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR 1.97 AND 1.98**

**Mail Stop: AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

June 23, 2005

SIR:

Pursuant to Applicants' duty of disclosure, enclosed please find copies of documents to be considered by the Examiner during examination of the above-identified application. Also enclosed is a Form PTO/SB/08A and B, listing the enclosed documents.

Of the enclosed documents, European Patent Application No. 459352 was listed in the International Search Report in connection with International (PCT) Application No. PCT/IB2003/003470, filed August 22, 2003, of which the above-identified application is a National Stage application filed under 35 USC 371. The remaining enclosed documents are discussed in the specification of the above-identified application, e.g., on pages 2 and 3 thereof.

This Information Disclosure Statement is being submitted prior to a first Office Action on the merits in the above-identified application. Accordingly, requirements of 37 CFR 1.97(b) are satisfied.


To the extent that the enclosed documents are not in English, it is respectfully submitted that requirements of 37 CFR 1.98(a)(3) are satisfied by discussion thereof in the specification of the above-identified application, on page 3 thereof.

In view of the foregoing, it is respectfully submitted that all applicable requirements of 37 CFR 1.97 and 1.98 have been satisfied, in connection with the present submission of the enclosed documents. Accordingly, consideration of the enclosed documents, during examination of the above-identified application, is respectfully requested.

Applicants request any shortage of fees in connection with the filing of this paper be charged to the Deposit Account of Antonelli, Terry, Stout & Kraus, LLP, Deposit Account No. 01-2135 (case 506.44792X00), and any excess of fees paid be credited to such Deposit Account.

Respectfully submitted,

**ANTONELLI, TERRY, STOUT & KRAUS, LLP**

By   
William I. Solomon  
Registration No. 28,565


WIS/ksh  
1300 N. Seventeenth Street  
Suite 1800  
Arlington, Virginia 22209  
Tel: 703-312-6600  
Fax: 703-312-6666



Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet	1	of	2
-------	---	----	---

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <b>June 23, 2005</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/525,326
				Filing Date	02/22/2005
				First Named Inventor	M.SAKI
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	506.44792X00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		K. Zhu, et al., "Sphingosylphosphorylcholine and Lysophosphatidylcholine Are Ligands for the G Protein-coupled Receptor GPR4*", <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 44, pp. 41325-41335 (November 2, 2001).	
		M. S. Mahadevan, et al., "Isolation of a Novel G Protein-Coupled Receptor (GPR4) Localized to Chromosome 19q13.3", <i>Genomics</i> , Vol. 30, pp. 84-88 (1995).	
		S. K. Chhabra, et al., "Increased intracellular calcium and decreased activities of leucocyte Na <sup>+</sup> , K <sup>+</sup> -ATPase and Ca <sup>2+</sup> -ATPase in asthma", <i>Clinical Science</i> , Vol. 97, pp. 595-601 (1999).	
		S. K. Gupta, et al., "A Placebo Controlled Trial of Two Dosages of LPC Antagonist - Choline in the Management of Bronchial Asthma", <i>The Indian Journal of Chest Diseases &amp; Allied Sciences</i> , Vol. 39, pp. 149-156 (1997).	
		F. H. Chilton, et al., "Antigen-induced Generation of Lyso-Phospholipids in Human Airways", <i>Journal of Exp. Med.</i> , Vol. 183, pp. 2235-2245 (May 1996).	
		J. Lehuède, et al., "Aminomethylation de l'homoacridane, de l'iminodibenzyle et de l'iminostilbene", <i>Bulletin De La Societe Chimique De France</i> , No. 5-6, pp. 185-191 (1981).	
		M. Miocque, et al., "Derives de l'imipramine: aminomethylation de la diphenylamine et de l'iminodibenzyle", <i>Eur. J. Med. Chem.</i> , Vol. 12, No. 3, pp. 219-225 (May-June 1977).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2